DIA
30.1.2024 10:01:28 CET | Business Wire | Press release
DIA, a global organization of life sciences professionals, will emphasize how collaboration and innovation can support sustainability in healthcare at DIA Europe 2024, to be held March 12-14 at Square Brussels Convention Centre in Brussels.
DIA Europe, the largest and most forward-looking neutral healthcare conference on the continent, is the only event that gives representatives from the European Commission, the European Medicines Agency (EMA), the World Health Organization (WHO), the Heads of Medicines Agencies (HMA), national competent authorities, healthcare professionals, and patient populations the opportunity to come together to shape key policy decisions.
Now in its 36th year, DIA Europe will feature discussions on the environmental footprint of pharmaceuticals and drug development. Panelists will explore optimal sustainability practices with more than 250 guest speakers across 11 rich content tracks that comprise 100-plus sessions, including much-anticipated "DIAmond sessions" and town halls. They will also participate in collaboration hubs, showcases, and workshops designed to drive change and innovative thinking.
"Sustainability is one of the defining challenges in healthcare today," said Ania Mitan, DIA's Senior Vice President and Managing Director, EMEA and India. "No organization can tackle it alone, but through open dialogue, partnership across industry, government, and academia, and listening to the patient's perspective, we can drive real progress. Learning from each other will empower us to develop new approaches that benefit patients, society, and our planet."
Attendees will hear from more than 25 EMA executives, including Emer Cooke, the Executive Director of the EMA and the Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA); Martin Harvey Allchurch, the EMA's Head of International Affairs; and Dr. Peter Arlett, the EMA's Head of Data Analytics and Methods Task Force.
Leda Stott, a Senior Research Fellow at the Innovation and Technology for Development Centre at the Technical University of Madrid and an authority on multi-stakeholder collaboration; Veronique Toully, the Global Head of Sustainability, Corporate Affairs and Risks at UCB; and Dr. Glenn Wells, Chief Partnerships Officer at the Medicines and Healthcare Products Regulatory Agency (MHRA), will deliver a keynote address that examines healthcare's most pressing sustainability challenges.
Other can't-miss sessions include:
— "EU Regulatory Town Hall: The New Pharmaceutical Legislation": Explore how we are increasing availability and access to novel healthcare solutions.
— "Digital Transformation in the EU Regulatory Space": Discuss how Europe is building the foundations for its digital transformation in the regulatory space for the next 10 years.
— "Complexity: Interplay and Interface of Different Legislations": Learn how we can drive medicine research, development, and manufacturing amid an increasingly complicated landscape of EU policies and regulations.
Three new content tracks this year will cover emerging trends in healthcare: Artificial Intelligence, Data Science, and Real-World Evidence; Innovative Therapies, Precision Medicine, and Diagnostics; and International Collaboration and Regional Updates.
DIA is celebrating 60 years of bringing together leading minds to foster innovation, collaboration, and advancement in global healthcare.
At DIA Europe, everyone meets on equal terms. To register to attend as a participant or media member, visit https://www.diaglobal.org/Flagship/DIA-Europe-2024.
About DIA
DIA is a leading global life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.
Learn more at DIAglobal.org, and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130133798/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 17:20:00 CEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release
Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom